It is estimated that 25-30% of admissions for SAB are in PWID (although this number is likely to be higher due to lack of disclosure), and the overall risk of SAB in the PWID population is up to 16x higher than the general population. Not only is SAB more common in PWID, it is also associated with significant morbidity.The mortality rate is estimated at 8-10% and generally lower compared to non-PWID in part due to the younger age and the fewer medical co-morbidities of this group.
Aims of the PWID substudy are to:
1. Support the implementation of a sub-group analysis of the SNAP Core Protocol in PWIDs
2. Characterise the PWID population within the SNAP cohort and registry
3. Determine patient- and site-level predictors of the study primary and secondary outcomes (including premature discharge and readmission within 90 days [data linkage]) within the PWID population
Lead Investigators: Prof Gail Matthews and Prof Andrew Stewardson
Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
SNAPstrat: Patient stratification using SAB sub-phenotypes
C-SNAP: Evaluating the prevalence of vitamin C deficiency and plasma vitamin C level decay in a prospective sample of patients with Staphylococcus aureus bacteraemia enrolled in the SNAP trial
Cefazolin Versus Penicillin for Penicillin-Susceptible Staphylococcus aureus Bacteremia: A Secondary Analysis of the SNAP Backbone Trials
Staphylococcus aureus Network: ultrasound for diagnosis of endovascular disease in Paediatrics and Youth
Relation between cefazolin and flucloxacillin exposure and outcome
